longevity – OpenClaw Skill

---

name: longevity description: Evaluates longevity interventions using evidence tiers. Provides research evaluation framework and curated high-value insights on supplements, sleep, exercise, and protocols. Activate for anti-aging, healthspan, supplement evaluation, or research paper analysis. license: MIT metadata: version: "2.0"

Longevity Research Framework

Evidence-based longevity evaluation assistant. Teaches how to assess interventions using research methodology, not prescription. Provides curated non-obvious insights demonstrating the evaluation framework.

When to Activate

Trigger keywords: longevity, anti-aging, healthspan, lifespan, supplement evaluation, research paper analysis, evidence tier, biomarker interpretation, sleep optimization, exercise protocol, Bryan Johnson, Blueprint, mitochondria, autophagy, senolytics.

Evidence Tiers

Tier	Definition	Example
A	Multiple RCTs, meta-analyses, consistent results	Creatine for muscle
B	Single RCT or large cohort, emerging human data	Urolithin-A
C	Mechanistic/animal studies, small human trials	Most senolytics
D	Anecdotal, theoretical, n=1	Novel peptides

Research Evaluation Framework

Study Design Hierarchy

1. Systematic review / meta-analysis
2. Randomized controlled trial (RCT)
3. Cohort study (prospective > retrospective)
4. Case-control study
5. Case series / case reports
6. Mechanistic / animal studies
7. Expert opinion / theoretical

Assessment Checklist

• Sample size: Adequately powered? (n>100 for most outcomes)
• Duration: Appropriate for endpoint? (bone density needs years, not weeks)
• Population: Relevant to you? (young athletes ≠ older adults)
• Effect size: Clinically meaningful or just statistically significant?
• Replication: Confirmed by independent groups?
• Conflict of interest: Industry-funded? Disclosed relationships?

Red Flags

• Single study with extraordinary claims
• Surrogate endpoints only (biomarker change without clinical outcome)
• Cherry-picked timepoints or subgroups
• No control group or inadequate blinding
• Massive effect sizes (>50% improvement = suspicious)
• Published only in predatory journals
• Funded entirely by supplement manufacturer
• Authors selling the product

---

Alpha Discovery Framework

Use these patterns to identify non-obvious insights in longevity research:

Dosing Assumptions

• Standard dose may not apply to all outcomes (tissue-specific thresholds)
• "More is better" often has inverse U-curve (melatonin, antioxidants)
• Saturation points differ by target (muscle vs. brain for creatine)

Timing & Context

• Relative timing matters (cold exposure vs. training window)
• Circadian timing affects efficacy (eating window, supplement timing)
• Cycling may be required (adaptation, tolerance, microbiome shifts)

Form & Bioavailability

• Same compound, different absorption (ethyl ester vs. triglyceride omega-3)
• Conversion dependencies (ellagitannins → urolithin-A requires specific gut bacteria)
• Cofactor requirements (fat-soluble vitamins need dietary fat)

Synergies & Antagonisms

• Required pairings (D3 without K2 may cause harm)
• Absorption competition (calcium and magnesium compete)
• Timing conflicts (iron and coffee, cold and hypertrophy)

Population Specificity

• Age-dependent responses (fasting + muscle loss in older adults)
• Sex differences in metabolism
• Genetic responders vs. non-responders (APOE and saturated fat)

Mechanism vs. Outcome

• Plausible mechanism ≠ proven clinical benefit
• Surrogate endpoints (biomarkers) ≠ real outcomes (mortality, function)
• Animal doses rarely translate directly to humans

---

Example Alpha

The following examples demonstrate the discovery framework above. These are illustrative, not exhaustive—use the framework to evaluate new interventions.

Creatine: 15g for Cognitive Benefits

• Common belief: 5g saturates muscle, same dose works for brain
• Alpha: Serum creatine must rise high enough to cross blood-brain barrier and increase brain phosphocreatine. 5g saturates muscle but doesn't reliably raise brain levels.
• Evidence: Multiple studies show cognitive benefits at 15-20g; 5g studies often null for cognition
• Tier: B (emerging human data, mechanism understood)
• Practical: Split 15g into 3x5g doses to avoid GI distress

Melatonin: 300mcg Outperforms 1mg+

• Common belief: More melatonin = better sleep
• Alpha: Body produces ~300mcg endogenously. Supraphysiological doses (1-10mg) cause next-day grogginess, may affect cognition long-term, and create dependency via receptor downregulation.
• Evidence: Meta-analyses show 300mcg effective; higher doses don't improve outcomes
• Tier: A (multiple meta-analyses)
• Practical: Start at 300mcg; most commercial products are 10-30x too high

Urolithin-A: Mitophagy Without Pomegranate Roulette

• Common belief: Eat pomegranates for mitochondrial health
• Alpha: Urolithin-A (the active compound) requires gut bacteria conversion from ellagitannins. Only ~40% of people have the right microbiome. Direct supplementation bypasses this.
• Evidence: PMC9133463, Timeline nutrition RCTs show mitophagy activation
• Tier: B (human RCTs, mechanism validated)
• Practical: 500-1000mg daily; one of few compounds with direct mitophagy evidence in humans

Sleep Timing > Sleep Duration

• Common belief: Get 8 hours, timing doesn't matter
• Alpha: Circadian rhythm governs 100+ physiological processes. Shifting sleep window by 2 hours causes more dysfunction than losing 1-2 hours of sleep. Late sleep (2am-10am) worse than short sleep (11pm-6am).
• Evidence: Chronobiology research, shift-worker health outcomes
• Tier: A (strong epidemiological + mechanistic)
• Practical: Consistent bed/wake times matter more than duration optimization

Skin Damage: Cumulative and Irreversible

• Common belief: Damage can be repaired with skincare products
• Alpha: UV exposure causes cumulative DNA damage. Photoaging is largely irreversible. Prevention (sunscreen, clothing) has 100x ROI vs. treatment.
• Evidence: Dermatology consensus, twin studies
• Tier: A (decades of evidence)
• Practical: Daily SPF 30+ on face/hands is highest-yield longevity intervention for appearance

Zone 2 Cardio: Mitochondrial Biogenesis

• Common belief: HIIT is more efficient, Zone 2 is wasted time
• Alpha: Zone 2 (can talk but not sing) specifically drives mitochondrial biogenesis and fat oxidation capacity. HIIT builds different adaptations. Both needed, but Zone 2 is undervalued.
• Evidence: Exercise physiology, Inigo San Millan research
• Tier: A (extensive mechanistic + performance data)
• Practical: 3-4 hours/week Zone 2; most people go too hard and miss the adaptation

Cold Exposure: Timing Matters for Hypertrophy

• Common belief: Cold exposure is universally beneficial
• Alpha: Cold within 4 hours post-strength training blunts muscle protein synthesis and hypertrophy signaling. The inflammatory response you're suppressing is required for adaptation.
• Evidence: Multiple mechanism studies, athletic performance research
• Tier: B (consistent mechanism data, some human trials)
• Practical: Cold exposure on rest days or 6+ hours after strength training

Berberine: Cycling Required

• Common belief: Take daily like other supplements
• Alpha: GI microbiome adapts to berberine, reducing effectiveness. Also, berberine's metformin-like effects may blunt some exercise adaptations.
• Evidence: Clinical practice patterns, mechanism studies
• Tier: B (clinical consensus, mechanism understood)
• Practical: 4-6 weeks on, 2 weeks off; avoid on heavy training days

K2 (MK-7) + D3: Required Pairing

• Common belief: Vitamin D alone is fine
• Alpha: D3 increases calcium absorption. Without K2 to direct calcium to bones, it may deposit in arteries. K2 activates matrix-GLA protein and osteocalcin.
• Evidence: Multiple RCTs, Rotterdam Study correlations
• Tier: B (mechanistically clear, human outcome data emerging)
• Practical: 100-200mcg MK-7 per 5000 IU D3; take together with fat

Omega-3: Form Affects Absorption 3x

• Common belief: EPA/DHA amount is what matters
• Alpha: Triglyceride and phospholipid forms have 3x better absorption than ethyl ester (most common in cheap supplements). Ethyl ester requires more fat for absorption.
• Evidence: Bioavailability studies, head-to-head comparisons
• Tier: A (well-established pharmacokinetics)
• Practical: Pay more for triglyceride form or take ethyl ester with high-fat meal

Collagen: 15g+ for Joint Benefits

• Common belief: Small amounts help skin/joints
• Alpha: Studies showing joint benefits used 10-15g doses. Lower doses may help skin hydration but don't move the needle on joint tissue synthesis.
• Evidence: Joint-specific RCTs used higher doses than skin studies
• Tier: B (human RCTs at effective dose)
• Practical: 15g+ if targeting joints; 5g may suffice for skin only

Fasting: Protein Timing Beats Duration

• Common belief: Longer fasts are better
• Alpha: Muscle protein synthesis (MPS) is pulsatile. Extending fasts beyond 16-18h risks muscle catabolism, especially over age 40. Early time-restricted eating (eating earlier in day) outperforms late eating windows.
• Evidence: MPS research, circadian metabolism studies
• Tier: B (mechanism clear, human data supportive)
• Practical: 16:8 with eating window 8am-4pm beats 20:4 with window 2pm-6pm

---

Safety Principles

1. Physician consultation: Required for existing conditions, medications, or symptoms
2. One variable at a time: Introduce supplements individually, 1-2 week gaps
3. Start at 50% dose: Titrate up based on response
4. Stop before surgery: Most supplements stopped 1-2 weeks pre-surgery
5. Watch for interactions: Blood thinners, thyroid meds, and blood pressure meds have many supplement interactions

This skill does not diagnose, treat, or prescribe. All information is educational.

---

Extended Capabilities

When tools are available:

• Web search: Query PubMed for recent studies, verify safety alerts
• File reading: Analyze uploaded lab results or research papers
• Calculation: HOMA-IR, dosing by body weight, cost-per-dose comparisons

Example queries for research:

• "[compound] site:pubmed.gov RCT 2024 OR 2025"
• "[supplement] meta-analysis systematic review"

---

Guidelines

Always

• Cite evidence tiers for recommendations
• Distinguish mechanism (plausible) from outcome (proven)
• Acknowledge uncertainty and individual variation
• Recommend professional consultation for medical concerns

Never

• Diagnose or prescribe
• Overstate evidence quality (C-tier is not "proven")
• Ignore potential interactions
• Guarantee outcomes